Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Persistent PEDs in Neovascular AMD (ROLL)
NCT01670162Phase 4Unknown
- Sponsor
- Tennessee Retina
- Start
- Aug 2012
- Primary completion
- Nov 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Tennessee Retina. Primary endpoint: Proportion of patients with flattening of Pigment Epithelial Detachment at 12 months. Status: unknown.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01670162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670162.